Bicycle Therapeutics Stock Analysis

BCYC Stock  USD 20.40  0.05  0.25%   
Bicycle Therapeutics is undervalued with Real Value of 27.96 and Target Price of 49.08. The main objective of Bicycle Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Bicycle Therapeutics is worth, separate from its market price. There are two main types of Bicycle Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Bicycle Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Bicycle Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.

Bicycle Stock Analysis Notes

About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bicycle Therapeutics recorded a loss per share of 3.28. The entity had not issued any dividends in recent years. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Bicycle Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. For more info on Bicycle Therapeutics please contact Kevin MBA at 44 1223 261 503 or go to https://www.bicycletherapeutics.com.

Bicycle Therapeutics Quarterly Total Revenue

2.68 Million

Bicycle Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bicycle Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bicycle Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bicycle Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 26.98 M. Net Loss for the year was (180.66 M) with loss before overhead, payroll, taxes, and interest of (67.15 M).
Bicycle Therapeutics currently holds about 372.77 M in cash with (60.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.56.
Over 92.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Bicycle Therapeutics Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bicycle Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Bicycle Largest EPS Surprises

Earnings surprises can significantly impact Bicycle Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-08-05
2020-06-30-0.48-0.67-0.1939 
2023-05-04
2023-03-31-1.07-1.3-0.2321 
2022-05-05
2022-03-31-0.68-0.93-0.2536 
View All Earnings Estimates

Bicycle Therapeutics Environmental, Social, and Governance (ESG) Scores

Bicycle Therapeutics' ESG score is a quantitative measure that evaluates Bicycle Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Bicycle Therapeutics' operations that may have significant financial implications and affect Bicycle Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Bicycle Stock Institutional Investors

Shares
Camber Capital Management Llc2024-09-30
915 K
Ecor1 Capital, Llc2024-09-30
910 K
Point72 Asset Management, L.p.2024-09-30
899.8 K
Bnp Paribas Investment Partners Sa2024-06-30
888.1 K
T. Rowe Price Associates, Inc.2024-06-30
798.5 K
Candriam Luxembourg S.c.a.2024-06-30
759.2 K
Woodline Partners Lp2024-06-30
586.6 K
Axa Sa2024-06-30
554.3 K
Parkman Healthcare Partners Llc2024-06-30
535.1 K
Baker Bros Advisors Lp2024-09-30
9.4 M
Deep Track Capital, Lp2024-09-30
3.5 M
Note, although Bicycle Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bicycle Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.41 B.

Bicycle Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.30)(0.32)
Return On Capital Employed(0.36)(0.38)
Return On Assets(0.30)(0.32)
Return On Equity(0.49)(0.51)

Management Efficiency

Bicycle Therapeutics has return on total asset (ROA) of (0.1502) % which means that it has lost $0.1502 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2667) %, meaning that it created substantial loss on money invested by shareholders. Bicycle Therapeutics' management efficiency ratios could be used to measure how well Bicycle Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.32. In addition to that, Return On Capital Employed is expected to decline to -0.38. At present, Bicycle Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 10.2 M, whereas Non Current Assets Total are forecasted to decline to about 18 M.
Last ReportedProjected for Next Year
Book Value Per Share 10.42  10.94 
Tangible Book Value Per Share 10.42  10.94 
Enterprise Value Over EBITDA(0.88)(0.93)
Price Book Value Ratio 1.73  1.65 
Enterprise Value Multiple(0.88)(0.93)
Price Fair Value 1.73  1.65 
Enterprise Value162 M153.9 M
The strategic vision of Bicycle Therapeutics management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Operating Margin
(23.86)
Beta
0.892
Return On Assets
(0.15)
Return On Equity
(0.27)

Technical Drivers

As of the 30th of November, Bicycle Therapeutics shows the risk adjusted performance of 0.0013, and Mean Deviation of 2.34. Bicycle Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Bicycle Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Bicycle Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Bicycle Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Bicycle Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bicycle Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bicycle Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bicycle Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Travis Thompson over a week ago
Disposition of 1109 shares by Travis Thompson of Bicycle Therapeutics at 9.82 subject to Rule 16b-3
 
Travis Thompson over two weeks ago
Disposition of 154 shares by Travis Thompson of Bicycle Therapeutics at 8.21 subject to Rule 16b-3
 
Travis Thompson over a month ago
Disposition of 153 shares by Travis Thompson of Bicycle Therapeutics at 22.26 subject to Rule 16b-3
 
Nicholas Keen over a month ago
Acquisition by Nicholas Keen of 28000 shares of Bicycle Therapeutics subject to Rule 16b-3
 
Travis Thompson over a month ago
Disposition of 153 shares by Travis Thompson of Bicycle Therapeutics at 22.26 subject to Rule 16b-3
 
Arroyo Santiago over three months ago
Acquisition by Arroyo Santiago of 120000 shares of Bicycle Therapeutics at 21.77 subject to Rule 16b-3
 
Skynner Michael over three months ago
Disposition of 967 shares by Skynner Michael of Bicycle Therapeutics at 19.64 subject to Rule 16b-3
 
Alistair Milnes over three months ago
Disposition of 967 shares by Alistair Milnes of Bicycle Therapeutics at 19.64 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over three months ago
Acquisition by Baker Bros. Advisors Lp of 196098 shares of Bicycle Therapeutics subject to Rule 16b-3
 
Baker Bros. Advisors Lp over six months ago
Acquisition by Baker Bros. Advisors Lp of 1429986 shares of Bicycle Therapeutics subject to Rule 16b-3
 
Bourque Janice over six months ago
Acquisition by Bourque Janice of 6000 shares of Bicycle Therapeutics subject to Rule 16b-3
 
Travis Thompson over six months ago
Disposition of 456 shares by Travis Thompson of Bicycle Therapeutics at 8.03 subject to Rule 16b-3

Bicycle Therapeutics Outstanding Bonds

Bicycle Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bicycle Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bicycle bonds can be classified according to their maturity, which is the date when Bicycle Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Bicycle Therapeutics Predictive Daily Indicators

Bicycle Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bicycle Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bicycle Therapeutics Corporate Filings

13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
F4
13th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
31st of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
23rd of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
4th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
19th of September 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
6th of August 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
10th of July 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Bicycle Therapeutics Forecast Models

Bicycle Therapeutics' time-series forecasting models are one of many Bicycle Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bicycle Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Bicycle Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bicycle Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bicycle shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bicycle Therapeutics. By using and applying Bicycle Stock analysis, traders can create a robust methodology for identifying Bicycle entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(6.64)(6.98)
Operating Profit Margin(7.04)(7.39)
Net Loss(6.70)(7.03)
Gross Profit Margin 0.76  0.80 

Current Bicycle Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bicycle analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bicycle analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
49.08Strong Buy13Odds
Bicycle Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bicycle analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bicycle stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bicycle Therapeutics, talking to its executives and customers, or listening to Bicycle conference calls.
Bicycle Analyst Advice Details

Bicycle Stock Analysis Indicators

Bicycle Therapeutics stock analysis indicators help investors evaluate how Bicycle Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bicycle Therapeutics shares will generate the highest return on investment. By understating and applying Bicycle Therapeutics stock analysis, traders can identify Bicycle Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow339.2 M
Long Term Debt30.7 M
Common Stock Shares Outstanding35.6 M
Total Stockholder Equity370.9 M
Tax Provision1.5 M
Property Plant And Equipment Net27.7 M
Cash And Short Term Investments526.4 M
Cash526.4 M
Accounts Payable13.1 M
Net Debt-481.5 M
50 Day M A23.7041
Total Current Liabilities69.5 M
Other Operating Expenses216.9 M
Non Current Assets Total33.5 M
Non Currrent Assets Other5.8 M
Stock Based Compensation32.5 M

Complementary Tools for Bicycle Stock analysis

When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Insider Screener
Find insiders across different sectors to evaluate their impact on performance